PaloMid 529 (P529)
PaloMid 529 (P529) Basic information
- Product Name:
- PaloMid 529 (P529)
- Synonyms:
-
- PaloMid 529 (P529)
- PaloMid 529
- 8-(1-Hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]-6H-dibenzo[b,d]pyran-6-one
- 8-(1-Hydroxyethyl)-2-Methoxy-3-((4-Methoxybenzyl)oxy)-6H-benzo[c]chroMen-6-one
- 3-(4-methoxybenzyloxy)-8-(1-hydroxyethyl)-2-methoxy-6H-benzo[c]chromen-6-one
- 8-(1-Hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]-6H-dibenzo[b,d]pyran-6-one Palomid 529 (P529) SG 00529
- SG 00529
- Palomid 529, >=98%
- CAS:
- 914913-88-5
- MF:
- C24H22O6
- MW:
- 406.43
- EINECS:
- 806-313-6
- Product Categories:
-
- Inhibitors
- API
- Mol File:
- 914913-88-5.mol
PaloMid 529 (P529) Chemical Properties
- Boiling point:
- 614.0±55.0 °C(Predicted)
- Density
- 1.280
- storage temp.
- -20°C
- solubility
- DMSO: soluble10mg/mL, clear
- form
- powder
- pka
- 11.79±0.20(Predicted)
- color
- white to beige
PaloMid 529 (P529) Usage And Synthesis
Uses
Palomid 529 is a novel non-steroidal small molecule inhibitor
Biological Activity
Palomid 529 (P529) inhibits the mTORC1 and mTORC2 complexes and reduces the phosphorylation of pAktS473, pGSK3βS9 and pS6, but has no effect on pMAPK and pAktT308. Phase 1.
in vivo
Palomid 529 (200 mg/kg/2d) inhibits C6V10 glioma tumor growth in nude mice following i.p. dosing. Analysis of signaling within the tumor lysates reveals that Palomid 529 (P529) also reduces AktS473 but not AktT308 signaling[1]. Palomid 529 (RES-529) has shown antitumor activity in a variety of mouse models, including those for glioblastoma, and prostate and breast cancer. In a C6V10 glioblastoma subcutaneous xenograft model, mice pretreated with Palomid 529 (200 mg/kg/2 days, intraperitoneal) 1 week before and for 3 weeks after a tumor cell injection showed an ~70% decrease in tumor volume compared with the control. In another glioblastoma tumor model using human U87 cells, mice treated with micronized Palomid 529 3 days after a tumor cell injection showed a reduction in tumor growth by ~78 and 29% with 50 and 25 mg/kg/2 days, intraperitoneal, Palomid 529, respectively, after 24 days compared with the control[2]. Palomid 529 (P529) is able to reduce tumor growth in a dose-dependent manner both in PC3 and 22rv1 xenografts. A 10, 47.6, and 59.3% reduction of tumor mass is demonstrated in mice bearing PC3 xenografts receiving 50, 100, and 200 mg/kg Palomid 529 respectively and a 9, 38.7, and 51.5% reduction of tumor mass in mice bearing 22rv1 xenografts receiving 50, 100, and 200 mg/kg Palomid 529 respectively[3].
target
mTORC1
IC 50
TORC1; TORC2
PaloMid 529 (P529)Supplier
- Tel
- sales@boylechem.com
- Tel
- 0531-88811783
- sales@trio-pharmatech.com
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Tel
- 86-21-34053660
- sale@labgogo.com
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988